Nick McAndrew, MD MSCE Clinical Instructor Division of Hematology / Oncology UCLA David Geffen School of Medicine discusses updates in Breast CancerSummary of 2019 practice changing studies Overall Survival UpdatesCDK 4/6 Inhibitors: MONALEESA 3, 7 and MONARCH 2, Adjuvant Pertuzumab: APHINITY, ER+, First PI3K Inhibitor Approval: SOLAR-1, HER2+, Tyrosine Kinase Inhibitors: NALA, HER2CLIMB, New ADC: DESTINY-Breast01Triple Negative, Checkpoint Inhibitor in mBC: IMpassion130 Neoadjuvant Checkpoint Inhibitors: KEYNOTE-522, NeoTRIP at the MOASC Summit 2020
Sponsors:
AbbVie
AMAG
AstraZeneca
Bayer
BeiGene
Clovis Oncology
Coherus
Daiichi-Sankyo
Dova Pharmaceuticals
Foundation Medicine
Jazz Pharmaceuticals
Merck
Pfizer Oncology
Puma Biotechnology
Tempus
Verastem oncology
Walgreens
Advertisement